Eliquis, Opdivo push up Bristol-Myers' quarterly ad spend

Bristol-Myers Squibb ($BMY) spent Q3 competing in a couple of hot market races--and for that, it needed more ad dollars. The company's advertising and product promotion costs rose 13% to $193 million for the period, following two quarters of double-digit decreases this year--and a 14% overall decrease for all of 2014. A fair share of that money went toward promoting Eliquis, which is chasing Johnson & Johnson ($JNJ) and Bayer's Xarelto and Boehringer Ingelheim's Pradaxa in the new-age anticoagulant market. And BMS also shelled out on checkpoint inhibitor Opdivo--up against Merck's ($MRK) Keytruda--with a DTC ad that first aired in September. More from FiercePharmaMarketing

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…